News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
708,368 Results
Type
Article (40923)
Company Profile (256)
Press Release (667189)
Multimedia
Podcasts (51)
Webinars (12)
Section
Business (206725)
Career Advice (2020)
Deals (35825)
Drug Delivery (95)
Drug Development (81294)
Employer Resources (172)
FDA (16380)
Job Trends (14986)
News (348799)
Policy (32860)
Tag
Academia (2597)
Accelerated approval (5)
Adcomms (20)
Allergies (86)
Alliances (50353)
ALS (91)
Alzheimer's disease (1400)
Antibody-drug conjugate (ADC) (130)
Approvals (16381)
Artificial intelligence (269)
Autoimmune disease (23)
Automation (16)
Bankruptcy (364)
Best Places to Work (11703)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (176)
Bladder cancer (78)
Brain cancer (27)
Breast cancer (287)
Cancer (2302)
Cardiovascular disease (179)
Career advice (1690)
Career pathing (30)
CAR-T (153)
Cell therapy (430)
Cervical cancer (21)
Clinical research (66200)
Collaboration (850)
Company closure (1)
Compensation (551)
Complete response letters (19)
COVID-19 (2615)
CRISPR (41)
C-suite (253)
Cystic fibrosis (102)
Data (2276)
Decentralized trials (2)
Denatured (18)
Depression (46)
Diabetes (276)
Diagnostics (6763)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (100)
Drug shortages (25)
Duchenne muscular dystrophy (96)
Earnings (87583)
Editorial (37)
Employer branding (21)
Employer resources (146)
Events (113804)
Executive appointments (740)
FDA (17709)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (767)
Gene editing (109)
Generative AI (24)
Gene therapy (309)
GLP-1 (714)
Government (4464)
Grass and pollen (4)
Guidances (108)
Healthcare (19014)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (119)
Indications (29)
Infectious disease (2761)
Inflammatory bowel disease (144)
Inflation Reduction Act (8)
Influenza (53)
Intellectual property (97)
Interviews (315)
IPO (16672)
IRA (41)
Job creations (3693)
Job search strategy (1435)
Kidney cancer (10)
Labor market (40)
Layoffs (474)
Leadership (17)
Legal (7962)
Liver cancer (78)
Lung cancer (323)
Lymphoma (155)
Machine learning (8)
Management (58)
Manufacturing (320)
MASH (70)
Medical device (13528)
Medtech (13533)
Mergers & acquisitions (19713)
Metabolic disorders (700)
Multiple sclerosis (82)
NASH (16)
Neurodegenerative disease (91)
Neuropsychiatric disorders (27)
Neuroscience (1947)
NextGen: Class of 2025 (6557)
Non-profit (4536)
Now hiring (40)
Obesity (371)
Opinion (205)
Ovarian cancer (77)
Pain (90)
Pancreatic cancer (88)
Parkinson's disease (150)
Partnered (21)
Patents (239)
Patient recruitment (116)
Peanut (47)
People (58004)
Pharmaceutical (64)
Pharmacy benefit managers (19)
Phase I (20623)
Phase II (29167)
Phase III (21706)
Pipeline (1280)
Policy (144)
Postmarket research (2567)
Preclinical (8780)
Press Release (66)
Prostate cancer (108)
Psychedelics (31)
Radiopharmaceuticals (253)
Rare diseases (381)
Real estate (6000)
Recruiting (65)
Regulatory (22551)
Reports (46)
Research institute (2361)
Resumes & cover letters (351)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (71)
Series A (131)
Series B (87)
Service/supplier (12)
Sickle cell disease (52)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (30)
Startups (3659)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (45)
The Weekly (31)
Vaccines (694)
Venture capitalists (42)
Weight loss (236)
Women's health (35)
Worklife (16)
Date
Today (291)
Last 7 days (867)
Last 30 days (2927)
Last 365 days (32890)
2025 (11373)
2024 (35518)
2023 (40432)
2022 (51549)
2021 (56105)
2020 (54582)
2019 (46972)
2018 (35404)
2017 (32524)
2016 (31989)
2015 (38123)
2014 (31796)
2013 (26920)
2012 (29106)
2011 (29799)
2010 (27788)
Location
Africa (734)
Alabama (53)
Alaska (7)
Arizona (234)
Arkansas (13)
Asia (38640)
Australia (6335)
California (6302)
Canada (2046)
China (532)
Colorado (270)
Connecticut (278)
Delaware (153)
Europe (83660)
Florida (929)
Georgia (214)
Idaho (57)
Illinois (551)
India (25)
Indiana (315)
Iowa (11)
Japan (168)
Kansas (105)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (913)
Massachusetts (4688)
Michigan (222)
Minnesota (404)
Mississippi (2)
Missouri (83)
Montana (27)
Nebraska (25)
Nevada (65)
New Hampshire (66)
New Jersey (1767)
New Mexico (30)
New York (1786)
North Carolina (1018)
North Dakota (8)
Northern California (2754)
Ohio (209)
Oklahoma (14)
Oregon (34)
Pennsylvania (1402)
Puerto Rico (12)
Rhode Island (33)
South America (1115)
South Carolina (25)
South Dakota (1)
Southern California (2375)
Tennessee (103)
Texas (940)
United States (23742)
Utah (188)
Virginia (150)
Washington D.C. (64)
Washington State (569)
West Virginia (3)
Wisconsin (65)
708,368 Results for "fujirebio diagnostics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Fujirebio Enhances Supply Chain Operations with Kinaxis
March 19, 2025
·
3 min read
Biotech Beach
Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics
Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic manufacturing, announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.
March 12, 2024
·
4 min read
Press Releases
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
December 23, 2024
·
3 min read
Fujirebio and Sysmex Sign Agreement for the Supply of Reagent Raw Materials in the Field of Immunoassay
Fujirebio Holdings, Inc. and Sysmex Corporation announced that they have signed an agreement for the mutual supply of reagent raw materials owned by both companies.
December 14, 2023
·
3 min read
Business
AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Strategic Partnership to Advance Biomarker Development for Alzheimer’s Disease and Neurodegeneration
Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced a strategic partnership to advance the development of biomarkers for Alzheimer’s disease and other neurodegenerative conditions.
March 8, 2023
·
3 min read
FDA
Fujirebio Submits FDA Regulatory Filing for Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease
September 25, 2024
·
3 min read
Fujirebio and Sysmex Expand CDMO Partnership into the Field of Neurodegenerative Diseases under Their Immunoassay Collaboration
Fujirebio Holdings, Inc. and Sysmex Corporation announced that they have entered into an agreement to expand their Contract Development and Manufacturing Organization partnership for Sysmex’s Automated Immunoassay System HISCL™-Series to include the field of neurodegenerative diseases, following the discussion based on the Basic Agreement on Business Collaboration in the field of immunoassay signed in October 2023*.
November 30, 2023
·
3 min read
Press Releases
Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast
April 29, 2025
·
1 min read
Business
Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics - March 12, 2024
Beckman Coulter Diagnostics today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.
March 12, 2024
·
4 min read
Pharm Country
Fujirebio Expands Its Alzheimer’s Disease Test Menu With the Much Awaited and Fully Automated Lumipulse® G pTau 217 Plasma Assay for Research Use Only (RUO)
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 Plasma assay for the fully automated LUMIPULSE G immunoassay systems.
December 22, 2023
·
3 min read
1 of 70,837
Next
